Tuesday, July 29, 2025
This study evaluates Endocan, an endothelial-derived protein, for its ability to discriminate between healthy and pathological peri-implant tissues and its diagnostic potential in peri-implant disease. A cross-sectional analysis of 62 peri-implant sites from 62 individuals, including 31 healthy sites, was conducted using clinical and radiographic parameters. The PICF was collected using a paper point methodology, and Endocan was quantified via enzyme-linked immunosorbent assay. Statistical analysis included multivariable linear regression models to assess associations between disease status and Endocan levels, adjusting for demographic factors. Results showed that healthy sites had the lowest Endocan levels (643.66 ± 128.49 ng/L), while peri-implantitis sites showed significantly elevated concentrations (841.83 ± 62.72 ng/L, p < 0.001). Peri-implant mucositis sites were not significantly different from healthy sites. Modeling revealed that peri-implantitis correlated with increased Endocan concentrations (B = 187.74, p < 0.001), while peri-implant mucositis showed no significant association. The study suggests that Endocan could serve as a biomarker for peri-implantitis, distinguishing between advanced pathology and mucositis. However, minimal research has examined Endocan concentrations in peri-implant tissues, and its potential for distinguishing between different stages of peri-implant disease remains unexplored. The null hypothesis assumes no significant variation in Endocan between healthy and pathological peri-implant locations. To assess and compare Endocan values in peri-implant crevicular fluid (PICF) between healthy and diseased peri-implant locations. To assess whether Endocan levels differ between peri-implant mucositis and peri-implantitis.
Reference: Evaluation of endocan biomarker levels in peri-implant crevicular fluid of healthy and diseased peri-implant sites: a cross-sectional studyLabels: BMC Oral Health
0 Comments